13 June 1997
Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral
Aleksandra Serafinowicz, Zbigniew Gaciong, Tomasz Cieciura, Teresa Baczkowska, Krzysztof Kukula, Mieczyslaw LaoAnn Transplant 1997; 2(2): 12-15 :: ID: 497146
Abstract
Neoral (NEO) is claimed to have better pharmacokinetics than standard preparation of cyclosporine (SIM) thus providing more reliable immunosuppression. We estimated safety and tolerability of NEO and compared pharmacokinetic parameters in 20 stable renal allograft recipients (RARs) converted from SIM to NEO treatment. Another 20 stable RARs continuously treated with SIM created a control group. Whole blood trough CsA level (Co) did not differ after conversion (SIM: 136.2:t33 ng/ml and NEO: 142.6:t 34 ng/ml). During therapy with NEO peak blood concentration (Cmax)was significandy higher (935.6:t 368 ng/mI) and occurred earlier (TmaxIhr. 36 min. :t30 min) as compared to the period on SIM(Cmax598 :t309 ng/ml. p=O.OI). Tmax=3 hr.:t Ih36 min., (p=O .01) respectively. AUC increased from 2975.4:t 1020 ngxhr/ml to 4236.1 :t 1188 ngxhr/ml (p
Keywords: Sandimmun Neoral, Pharmacokinetics
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review article
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860